WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
HK, Macao children representatives visit landmarks in Beijing
Padres break loose for 6 runs in the 5th inning and go on to beat the Brewers 7
What Salman Rushdie says in 'Knife,' the memoir about his stabbing
Sarah Jessica Parker divides opinion with enormous hat on set of And Just Like That
Messi sidelined for Argentina friendlies with injury
Padres' Jackson Merrill and Brewers' Jackson Chourio making big early impressions
Trump film shocks Cannes as former US President is depicted 'raping' his then
Messi sidelined for Argentina friendlies with injury
Analysis: Larson enters conversation with Verstappen as best drivers in the world
China's ice and snow industry shows promise in wake of Winter Olympics